EPHX2 and cardiovascular disorder: Thus, inhibition of sEH appears as an interesting pharmacological approach to increase the bioavailability of EETs in various pathological conditions in particular cardiovascular diseases (Wang Z. H. et al., 2013; Duflot et al., 2014).